Spero Therapeutics Long Term Debt

As of the most recent data (March 2026), SPRO shows a long-term debt of $510K. That compares with $2.2M in the prior-year period — down 76.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SPRO's long-term debt is now $510K (was $2.2M) — a 76.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Spero Therapeutics is outperforming or lagging.

Tracking SPRO's long-term debt over time shows whether Spero Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $510K That compares with $2.2M in the prior-year period — down 76.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Spero Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $510K) with ownership activity and broader fundamentals.

Spero Therapeutics's long-term debt is $510K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.